Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic BK virus-specific T cells
- Development stage
- Unknown
- Lead developer
- Cincinnati Children's Hospital Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic BK virus-specific T cells (BKV-CTL or BK-VST) are an investigational, unapproved adoptive cell therapy consisting of third-party (donor-derived), ex vivo-expanded, cryopreserved, partially HLA-matched, 'off-the-shelf' T cells that target BK virus-infected cells. Because BK virus and JC virus share high sequence homology in immunogenic proteins, these T cells also cross-reactively target JC virus-infected cells. This therapy is primarily investigated for the treatment of progressive multifocal leukoencephalopathy (PML), a life-threatening brain infection caused by the JC virus, as well as BK virus-associated hemorrhagic cystitis and BK virus nephropathy (BKVNP) in transplant recipients. Clinical studies have shown that these cells can cross the blood-brain barrier, reduce viral loads, and improve clinical symptoms in patients with PML.
- Other names
- BK virus-specific T cellsBK-VSTBKV-CTLBKV-specific T cellsallogeneic BK virus-specific cytotoxic T lymphocytesallogeneic BKV-specific T cells
Beyond the preview
Go deeper on allogeneic BK virus-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic BK virus-specific T cells.